Tadalafil therapy for pulmonary arterial hypertension.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Circulation

Title: Circulation

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1524-4539

ISSN (Print): 0009-7322

Publication date (Electronic): Jun 09 2009

Volume: 119

Issue: 22

Affiliations

[1 ] Institute of Cardiology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. nazzareno.galie@unibo.it

Article

Publisher Item ID: CIRCULATIONAHA.108.839274

DOI: 10.1161/CIRCULATIONAHA.108.839274

PubMed ID: 19470885

SO-VID: 1898288e-78e2-44e9-8b2a-6a45372bc6f1

History

Data availability:

Comments

Comment on this article

scite_

Cited by 223

See all cited by

- Version 1